- Home
- MET vs REGN Comparison
MET vs REGN Comparison
Compare MET & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MET
- REGN
- Stock Information
- Founded
- MET 1863
- REGN 1988
- Country
- MET United States
- REGN United States
- Employees
- MET N/A
- REGN N/A
- Industry
- MET Life Insurance
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- MET Finance
- REGN Health Care
- Exchange
- MET Nasdaq
- REGN Nasdaq
- Market Cap
- MET 49.7B
- REGN 59.5B
- IPO Year
- MET N/A
- REGN 1991
- Fundamental
- Price
- MET $80.84
- REGN $560.00
- Analyst Decision
- MET Strong Buy
- REGN Buy
- Analyst Count
- MET 10
- REGN 23
- Target Price
- MET $95.60
- REGN $794.83
- AVG Volume (30 Days)
- MET 2.8M
- REGN 972.9K
- Earning Date
- MET 10-29-2025
- REGN 10-30-2025
- Dividend Yield
- MET 2.81%
- REGN 0.63%
- EPS Growth
- MET 61.27
- REGN 5.03
- EPS
- MET 5.93
- REGN 39.67
- Revenue
- MET $73,011,000,000.00
- REGN $14,214,200,000.00
- Revenue This Year
- MET $6.71
- REGN N/A
- Revenue Next Year
- MET $3.61
- REGN $4.86
- P/E Ratio
- MET $13.64
- REGN $14.12
- Revenue Growth
- MET 6.17
- REGN 5.38
- 52 Week Low
- MET $65.21
- REGN $476.49
- 52 Week High
- MET $89.05
- REGN $1,170.58
- Technical
- Relative Strength Index (RSI)
- MET 57.59
- REGN 46.27
- Support Level
- MET $78.96
- REGN $552.98
- Resistance Level
- MET $80.33
- REGN $570.76
- Average True Range (ATR)
- MET 1.31
- REGN 15.16
- MACD
- MET -0.10
- REGN -2.91
- Stochastic Oscillator
- MET 66.97
- REGN 16.26
About MET MetLife Inc.
MetLife is one of the largest life insurers in the us by assets and provides a variety of insurance and financial-services products. It is organized into five segments: us, Asia, Latin America, Europe/Middle East/Africa, and MetLife Holdings. The us business contributes around 50% of earnings and is broken into the group benefits segment and the retirement solutions segment. The Asia segment contributes around 22% of earnings and is mainly composed of the Japan business, with increasing contributions from India, China, and Bangladesh. The company also holds leading market positions in Mexico and Chile, with the Latin America segment contributing around 13% of earnings. The EMEA and MetLife Holdings segments contribute around 4% and 11% of earnings, respectively.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).